Treatment of a pregnant woman with an angiotensin receptor blocking (ARB) agent can result in a number of changes in the fetus termed the ARB fetopathy. The findings are similar those seen with angiotensin converting enzyme (ACE) inhibitors. Therapy with an ARB is contraindicated during pregnancy.


Fetal changes may include:

(1) oligohydramnios

(2) renal insufficiency

(3) pulmonary hypoplasia (secondary to the renal insufficiency)

(4) limb contractures

(5) limb deformities including polydactyly


The fetus may be born prematurely.


The neonate may develop:

(1) hypotension

(2) end-stage renal failure

(3) salt-losing nephrogenic diabetes insipidus


To read more or access our algorithms and calculators, please log in or register.